- Home
- PBFS vs CAPR Comparison
PBFS vs CAPR Comparison
Compare PBFS & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- CAPR
- Stock Information
- Founded
- PBFS 1889
- CAPR 2005
- Country
- PBFS United States
- CAPR United States
- Employees
- PBFS N/A
- CAPR N/A
- Industry
- PBFS Banks
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PBFS Finance
- CAPR Health Care
- Exchange
- PBFS Nasdaq
- CAPR Nasdaq
- Market Cap
- PBFS 302.3M
- CAPR 322.7M
- IPO Year
- PBFS N/A
- CAPR N/A
- Fundamental
- Price
- PBFS $12.41
- CAPR $9.07
- Analyst Decision
- PBFS
- CAPR Strong Buy
- Analyst Count
- PBFS 0
- CAPR 8
- Target Price
- PBFS N/A
- CAPR $24.75
- AVG Volume (30 Days)
- PBFS 24.9K
- CAPR 2.1M
- Earning Date
- PBFS 09-24-2025
- CAPR 08-13-2025
- Dividend Yield
- PBFS N/A
- CAPR N/A
- EPS Growth
- PBFS 50.26
- CAPR N/A
- EPS
- PBFS 0.91
- CAPR N/A
- Revenue
- PBFS $91,369,000.00
- CAPR $17,363,588.00
- Revenue This Year
- PBFS N/A
- CAPR $16.24
- Revenue Next Year
- PBFS N/A
- CAPR $328.11
- P/E Ratio
- PBFS $13.59
- CAPR N/A
- Revenue Growth
- PBFS 23.15
- CAPR N/A
- 52 Week Low
- PBFS $10.07
- CAPR $3.71
- 52 Week High
- PBFS $12.65
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- PBFS 55.69
- CAPR 56.72
- Support Level
- PBFS $12.30
- CAPR $7.20
- Resistance Level
- PBFS $12.47
- CAPR $8.55
- Average True Range (ATR)
- PBFS 0.22
- CAPR 0.66
- MACD
- PBFS -0.01
- CAPR 0.29
- Stochastic Oscillator
- PBFS 62.50
- CAPR 88.71
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.